<DOC>
	<DOCNO>NCT01051882</DOCNO>
	<brief_summary>The study evaluate safety , tolerability therapeutic effect ( preliminary efficacy ) injection autologous culture mesenchymal bone marrow stromal cell secrete neurotrophic factor ( MSC-NTF ) , possible treatment patient Amyotrophic Lateral Sclerosis ( ALS ) early progressive disease stage .</brief_summary>
	<brief_title>Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors ( MSC-NTF ) , ALS Patients .</brief_title>
	<detailed_description>This study single center trial conduct Department Neurology &amp; Laboratory Neuroimmunology , Hadassah Hebrew University Medical Center , Jerusalem Israel . All patient enrol documented history ALS disease prior study enrolment . Patients diagnose early stage ALS disease duration le 6 month patient diagnose progressive stage ALS disease duration 6-12 month . Overall , 24 patient recruit allocate base ALS disease severity 2 treatment group : Group A - 12 patient early ALS disease stage Group B - 12 patient progressive ALS disease . Eligible patient enrol study observe every 2 week `` run period '' 3 month determination progression rate disease . During `` run period '' 6 week follow enrollment , patient study group undergo Bone Marrow Aspiration procedure MSC-NTF cell produce bone marrow aspirate base Brainstorm Cell Therapeutics Ltd proprietary method . On last `` run period '' visit , patient study group undergo treatment MSC-NTF transplant IM IT injection early progressive ALS patient respectively . After MSC-NTF transplantation patient observe monthly basis post treatment follow period 6 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . El Escorial criterion definite probable ALS 2 . Either men non pregnant woman 2075 year age . 3 . Patient mentally intact psychologically stable 4 . For early stage ALS Patients ALSFRSR scale least 30 disease duration le 2 years.Or , progressive stage ALS Patients ALSFRSR scale 1530 disease duration le 2 year 5 . For early stage ALS Patient sufficiently bulky muscle . Or , progressive stage ALS Patient least 60 % FVC 6 . Participant understands nature procedure provide write informed consent prior study procedure . 1 . Positive test HBV , HCV , HIV Mycoplasma . 2 . High protein CSF . 3 . Lymphocytosis CSF . 4 . Positive antiGM1 antibody . 5 . Patient significant conduction block slow nerve conduction velocity ( reduction 30 % ) confirm nerve conduction velocity EMG study . 6 . The patient respiratory dependent . 7 . Renal failure , impaired hepatic function 8 . Patients suffer significant cardiac disease , malignant disease disease may risk patient interfere ability interpret result 9 . Active infection . 10 . Participation another clinical trial within 1 month prior start study . 11 . Subject unwilling unable comply requirement protocol . 12 . Patient treat previously cellular therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Mesenchymal Stromal Cells ( MSC )</keyword>
	<keyword>Amyotrophic Lateral Sclerosis ( ALS )</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Neurodegeneration</keyword>
	<keyword>Stem cell</keyword>
	<keyword>ALS</keyword>
</DOC>